Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M327Revenue $M3.1Net Margin (%)-382.7Z-Score-5.8
Enterprise Value $M281EPS $-1.1Operating Margin %-555.5F-Score5
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-382.7Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %-31.0Quick Ratio3.5Cash flow > EarningsN
Price/Sales58.05-y EBITDA Growth Rate %-24.0Current Ratio3.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-29.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-67.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M62.7ROI % (ttm)-60.6Gross Margin Increase y-yY

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGENGeorge Soros 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 5.2278%Sold Out0
AGENJean-Marie Eveillard 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 5.2278%Sold Out0
AGENGeorge Soros 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 5.2248%New holding, 102200 sh.102,200
AGENJean-Marie Eveillard 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 5.2248%New holding, 200000 sh.200,000
AGENRobert Bruce 2012-06-30 Buy 0.52%$4.84 - $6.9
($5.78)
$ 5.22-10%New holding, 233515 sh.233,515
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGEN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AGEN Robert Bruce 2014-09-30233,5150.370.2
Premium Most recent portfolio changes are included for Premium Members only!


AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
QVT Associates GP LLC10% Owner 2015-01-09Sell2,343,630$5.31-1.69view
Wentworth KerryVP, Clinical, Reg & Qual 2014-02-26Sell5,000$54.4view
Malik ShahzadDirector 2014-02-12Sell0$04.4view
QVT Associates GP LLC10% Owner 2014-02-05Sell0$04.4view
Valentine KarenVP General Counsel 2014-01-23Sell2,850$3.549.14view
Baysal OzerChief Business Officer 2013-06-13Sell0$049.14view
Sharp ShaliniDirector 2013-01-30Sell288$4.3619.72view
Sharp ShaliniDirector 2012-10-31Sell288$4.418.64view
Sharp ShaliniDirector 2012-08-29Sell288$4.6412.5view
Valentine KarenVP and General Counsel 2008-06-04Sell0$012.5view

Press Releases about AGEN :

    Quarterly/Annual Reports about AGEN:

    News about AGEN:

    Articles On GuruFocus.com
    rusty Jan 26 2015 
    Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
    Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 10 2012 
    5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
    Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
    Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
    Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
    Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
    Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
    Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

    More From Other Websites
    Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics Jan 23 2015
    Agenus (AGEN) Shares March Higher, Can It Continue? - Tale of the Tape Jan 16 2015
    The Zacks Analyst Blog Highlights: NPS Pharmaceuticals, Celgene, Pharmacyclics, Agenus and Incyte -... Jan 15 2015
    AstraZeneca Inks Immuno-Oncology Agreement with Omnis - Analyst Blog Jan 14 2015
    Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst... Jan 14 2015
    Agenus, Inc. - "2015: Poised To Be Another Transformative Year for Agenus" Jan 12 2015
    Cramer's executive cut: CEOs on taxes, tech & biotech Jan 09 2015
    AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jan 09 2015
    Has Agenus Run Too Much? Jan 09 2015
    Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Jan 09 2015
    Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m.... Jan 09 2015
    Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Jan 09 2015
    AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 18 2014
    Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant Dec 18 2014
    AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 11 2014
    Celldex (CLDX) in Focus: Stock Tanks 21% Nov 06 2014
    Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session Nov 05 2014
    10-Q for Agenus, Inc. Nov 03 2014
    AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 31 2014
    Agenus posts 3Q loss Oct 31 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK